Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The study aims to systematically examine various aspects of the anxiety associated with the COVID-19 pandemic in Germany. The data collection is carried out online with longitudinal repeated measurements.
Description: To investigate specific fears regarding the COVID-19 pandemic 9 self created items are used. Values ranging from 1 to 6, higher scores indicate a worse outcome.
Measure: Characteristics of COVID-19-related anxiety Time: 1 dayDescription: Modified German version of the DSM-5 Severity-Measure-For-Specific-Phobia-Adult-Scale by Beesdo-Baum et al. (2014). 10 items, values ranging from 1 to 5, higher scores indicate a worse outcome. The Scale was adapted to anxiety symptoms related to COVID-19.
Measure: COVID-19-related anxiety symptoms Time: 1 dayDescription: Self-efficacy and coping with the COVID-19 pandemic are measured with 13 self created items. Values ranging from 1 to 6; higher scores indicate a better outcome (except inverted items).
Measure: Self-efficacy and coping with COVID-19 Time: baseline (1 day) + after 3 weeks + after 6 weeks + after 9 weeks + after 6 months + after 12 monthsDescription: Personal consequences of the COVID-19 pandemic in the last three weeks are collected with five self-created items.
Measure: Consequences of COVID-19 in the last three weeks. Time: baseline (1 day) + after 3 weeks + after 6 weeks + after 9 weeks + after 6 months + after 12 monthsDescription: General illness attitudes are measured with 3 subscales (Worry about illness; Thanatophobia; Bodily preoccupations) of the German version of the Illness Attitude Scales (IAS) by Hiller & Rief (2004). 9 Items; values ranging from 1 to 5, higher scores indicate a worse outcome.
Measure: General Illness Attitude Time: baseline (1 day) + after 3 weeks + after 6 weeks + after 9 weeks + after 6 months + after 12 monthsDescription: Frequency, effects and formats of consumed media related to COVID-19 are measured with 5 self created items.
Measure: Media reporting Time: baseline (1 day) + after 3 weeks + after 6 weeks + after 9 weeks + after 6 months + after 12 monthsDescription: To screen for general anxiety and depressive symptoms the German version of the Patient Health Questionnaire-4 (PHQ-4) by Löwe (2015) is used. 4 items; values ranging from 0 to 3, higher scores indicate a worse outcome.
Measure: Ultra-brief screening scale for anxiety and depression Time: baseline (1 day) + after 3 weeks + after 6 weeks + after 9 weeks + after 6 months + after 12 monthsDescription: To investigate specific fears regarding the COVID-19 pandemic 9 self created items are used. Values ranging from 1 to 6, higher scores indicate a worse outcome.
Measure: Change in characteristics of COVID-19-related anxiety Time: Ebaseline (1 day) + after 3 weeks + after 6 weeks + after 9 weeks + after 6 months + after 12 monthsDescription: Modified German version of the DSM-5 Severity-Measure-For-Specific-Phobia-Adult-Scale by Beesdo-Baum et al. (2014). 10 items, values ranging from 1 to 5, higher scores indicate a worse outcome. The Scale was adapted to anxiety symptoms related to COVID-19.
Measure: Change in COVID-19-related anxiety symptoms Time: baseline (1 day) + after 3 weeks + after 6 weeks + after 9 weeks + after 6 months + after 12 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports